Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Inserm · Sorbonne Université · +26 more institutions
Abstract
Background & AimsElafibranor is an agonist of the peroxisome proliferator−activated receptor-α and peroxisome proliferator−activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).MethodsPatients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and laboratory evaluations were performed every 2 months…
Citation impact
- FWCI
- 87.53
- Percentile
- 100%
- References
- 39
Authors
69- VRVlad RatziuCorresponding
Inserm, Sorbonne Université, Centre de Recherche Saint-Antoine, Fondation pour l’innovation en Cadiométabolisme et Nutrition
- SAStephen A. Harrison
Brooke Army Medical Center, Joint Base San Antonio
- SFSven Francque
University of Antwerp, Antwerp University Hospital
- PBPierre Bédossa
Université Paris Cité, Hôpital Beaujon
- PLPhilippe Lehert
The University of Melbourne, UCLouvain
Topics & keywords
- Nonalcoholic steatohepatitis
- Agonist
- Steatohepatitis
- Fibrosis
- Receptor
- Internal medicine
- Peroxisome proliferator-activated receptor
- Chemistry
- Good health and well-being